Brii Biosciences presented data showing that patients with chronic hepatitis B who lost HBsAg after treatment with pegylated interferon alfa combined with elebsiran or BRII-179 maintained durable immune control after stopping therapy. Most HBsAg rebounds were low and HBV DNA rebounds were rare without significant liver enzyme increases, supporting the safe discontinuation of nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Shorter NRTI consolidation periods did not increase rebound risk, indicating potential for shorter or no consolidation in future treatments. These findings advance next-generation HBV cure strategies and encourage ongoing study results in 2026.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
